Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland. We used nonlinear mixed effects modelling of longi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:EBioMedicine
Hoofdauteurs: Huang, Yunda, Naidoo, Logashvari, Zhang, Lily, Carpp, Lindsay N., Rudnicki, Erika, Randhawa, April, Gonzales, Pedro, McDermott, Adrian, Ledgerwood, Julie, Lorenzo, Margarita M.Gomez, Burns, David, DeCamp, Allan, Juraska, Michal, Mascola, John, Edupuganti, Srilatha, Mgodi, Nyaradzo, Cohen, Myron, Corey, Lawrence, Andrew, Philip, Karuna, Shelly, Gilbert, Peter B., Mngadi, Kathryn, Lazarus, Erica
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2021
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841500/
https://ncbi.nlm.nih.gov/pubmed/33493795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2020.103203
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items